Efficacy and safety of triplecombination therapy with paclitaxel, cisplatin and TS-1 in patients with advanced gastric cancer / 肿瘤

ABSTRACT

Objective: To evaluate the efficacy and safety of triplecombination therapy with paclitaxel, cisplatin (intra-abdominal administration) and TS-1 in patients with advanced gastric cancer. Methods: Fifty eligible inpatients with advanced gastric cancer were recruited between January 2008 and January 2011 and treated with triple-combination therapy with paclitaxel (intravenous administration), cisplatin (intra-abdominal administration) and TS-1 (oral administration). The short-term response and adverse reactions were evaluated. The average follow-up time was 11.4 months. The PFS (progression-free survival) and OS (overall survival) were calculated. Results: Of 50 patients, 5 patients achieved complete response and 23 patients achieved partial response, and the objective response rate was 56%. The median PFS was 6.0 months (95% confidence interval 3.4-8.6 months) and the median OS was 13.0 months (95% confidence interval 7.9-18.1 months). The major adverse reactions were gastrointestinal reactions, hematologic toxicities and fatigue. Most of these adverse reactions were grades II Grades II adverse reactions were observed in three patients (one had serious vomiting, two had liver dysfunction). The bowel obstruction was relieved after two cycles of chemotherapy in 2 patients who had incomplete bowel obstruction before chemotherapy, and the chemotherapy-associated bowel obstruction after two cycles of chemotherapy occurred in another patient who had no bowel obstruction before chemotherapy. Conclusion: The triple combination therapy with paclitaxel, cisplatin and TS-1 demonstrates benefits in short-term response and the survival for patients with advanced gastric cancer, and it is also well-tolerated. © 2012 by Tumor.